Further, KEGG pathway analysis revealed that these core targets were mainly related to the PI3K-Akt signalling pathway, ubiquitin-mediated proteolysis, estrogen signalling pathway, MAPK signalling pathway, TGF-beta signalling pathway, etc. The abovementioned evidence suggests the clinically promising potential of YZQX in the treatment of AD comorbidity with depression. The gene discussed is AKT1; the disease is depressive symptom measurement.